BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33317068)

  • 41. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
    Patel HJ; Patel PD; Ochiana SO; Yan P; Sun W; Patel MR; Shah SK; Tramentozzi E; Brooks J; Bolaender A; Shrestha L; Stephani R; Finotti P; Leifer C; Li Z; Gewirth DT; Taldone T; Chiosis G
    J Med Chem; 2015 May; 58(9):3922-43. PubMed ID: 25901531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing the chemical diversity of an hsp90 database.
    Audisio D; Messaoudi S; Ijjaali I; Dubus E; Petitet F; Peyrat JF; Brion JD; Alami M
    Eur J Med Chem; 2010 May; 45(5):2000-9. PubMed ID: 20170986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics studies.
    Abbasi M; Amanlou M; Aghaei M; Bakherad M; Doosti R; Sadeghi-Aliabadi H
    J Biomol Struct Dyn; 2020 Aug; 38(12):3462-3473. PubMed ID: 31452440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
    Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
    Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.
    Dymock B; Barril X; Beswick M; Collier A; Davies N; Drysdale M; Fink A; Fromont C; Hubbard RE; Massey A; Surgenor A; Wright L
    Bioorg Med Chem Lett; 2004 Jan; 14(2):325-8. PubMed ID: 14698151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crystal structure of the middle and C-terminal domains of Hsp90α labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target.
    Peng S; Woodruff J; Pathak PK; Matts RL; Deng J
    Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):571-585. PubMed ID: 35503206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards the In-silico Design of New HSP90 Inhibitors: Molecular Docking and 3D-QSAR CoMFA Studies of Tetrahydropyrido [4, 3-d] Pyrimidine Derivatives as HSP90 Inhibitors.
    Sepehri B; Ghavami R
    Med Chem; 2018; 14(5):439-450. PubMed ID: 29564982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors.
    Yang Y; Liu H; Du J; Qin J; Yao X
    J Mol Model; 2011 Dec; 17(12):3241-50. PubMed ID: 21369933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    J Biomol Struct Dyn; 2018 May; 36(6):1463-1478. PubMed ID: 28482755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
    Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Orally active purine-based inhibitors of the heat shock protein 90.
    Biamonte MA; Shi J; Hong K; Hurst DC; Zhang L; Fan J; Busch DJ; Karjian PL; Maldonado AA; Sensintaffar JL; Yang YC; Kamal A; Lough RE; Lundgren K; Burrows FJ; Timony GA; Boehm MF; Kasibhatla SR
    J Med Chem; 2006 Jan; 49(2):817-28. PubMed ID: 16420067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
    Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD
    Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors.
    Shao LD; Su J; Ye B; Liu JX; Zuo ZL; Li Y; Wang YY; Xia C; Zhao QS
    J Med Chem; 2017 Nov; 60(21):9053-9066. PubMed ID: 29019670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
    Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
    Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
    Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
    Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
    Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
    Bhatia S; Diedrich D; Frieg B; Ahlert H; Stein S; Bopp B; Lang F; Zang T; Kröger T; Ernst T; Kögler G; Krieg A; Lüdeke S; Kunkel H; Rodrigues Moita AJ; Kassack MU; Marquardt V; Opitz FV; Oldenburg M; Remke M; Babor F; Grez M; Hochhaus A; Borkhardt A; Groth G; Nagel-Steger L; Jose J; Kurz T; Gohlke H; Hansen FK; Hauer J
    Blood; 2018 Jul; 132(3):307-320. PubMed ID: 29724897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.